Clinical trial
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
NCT02654132 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 18, 2016
- Completion date
- October 21, 2021
- Enrollment
- 117 (actual)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.